- Home
- Publications
- Publication Search
- Publication Details
Title
Protein Kinase Targets in Breast Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 12, Pages 2543
Publisher
MDPI AG
Online
2017-11-28
DOI
10.3390/ijms18122543
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway
- (2017) Hongyu Shen et al. GENE
- PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases
- (2017) Ling-Li Wang et al. HUMAN PATHOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer
- (2017) Junko Tsuchida et al. MEDIATORS OF INFLAMMATION
- PLK1, A Potential Target for Cancer Therapy
- (2017) Zhixian Liu et al. Translational Oncology
- Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
- (2017) Yahong Wang et al. TUMOR BIOLOGY
- Overexpression of sphingosine kinase 1 is predictive of poor prognosis in human breast cancer
- (2017) Ya-Jing Zhu et al. Oncology Letters
- MicroRNA-128 promotes apoptosis in lung cancer by directly targeting NIMA-related kinase 2
- (2017) Dejian Zhao et al. Thoracic Cancer
- Deguelin inhibits epithelial-to-mesenchymal transition and metastasis of human non-small cell lung cancer cells by regulating NIMA-related kinase 2
- (2017) Dejian Zhao et al. Thoracic Cancer
- Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1
- (2017) Heba Alshaker et al. Scientific Reports
- Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
- (2017) I-Chun Chen et al. Scientific Reports
- Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
- (2016) K. B. Wisinski et al. CLINICAL CANCER RESEARCH
- Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER + Breast Cancer
- (2016) Sarah R. Hosford et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
- (2016) C. X. Ma et al. CLINICAL CANCER RESEARCH
- Neratinib for the treatment of breast cancer
- (2016) Annemie Prové et al. EXPERT OPINION ON PHARMACOTHERAPY
- Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond
- (2016) Józefa Węsierska-Gądek et al. Future Medicinal Chemistry
- MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway
- (2016) Hongyu Shen et al. GENE
- The Aurora kinase inhibitors in cancer research and therapy
- (2016) Jonas Cicenas JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeting the Breast Cancer Kinome
- (2016) Samantha M. Miller et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Lessons from breast cancer trials of HER2-kinase inhibitors
- (2016) Ian E Krop LANCET ONCOLOGY
- Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway
- (2016) Brendan C. Luey et al. Molecular Cancer
- Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
- (2016) C. Stottrup et al. MOLECULAR CANCER THERAPEUTICS
- Aurora A kinase activates YAP signaling in triple-negative breast cancer
- (2016) S-S Chang et al. ONCOGENE
- Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells
- (2016) RUBICELI MEDINA-AGUILAR et al. ONCOLOGY REPORTS
- Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
- (2016) Saya H. Ebbesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer
- (2016) Lichao Sun et al. Oncotarget
- Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death
- (2016) So Jung Park et al. Oncotarget
- Principles for Developing Patient Avatars in Precision and Systems Medicine
- (2016) Sherry-Ann Brown Frontiers in Genetics
- Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
- (2015) P. G. Nuciforo et al. ANNALS OF ONCOLOGY
- Quercetin Increase the Chemosensitivity of Breast Cancer Cells to Doxorubicin Via PTEN/Akt Pathway
- (2015) Shi-zheng Li et al. Anti-Cancer Agents in Medicinal Chemistry
- Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells
- (2015) Maximino Redondo et al. ANTI-CANCER DRUGS
- Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer
- (2015) Kerem Okutur et al. Asian Pacific Journal of Cancer Prevention
- Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss
- (2015) Ting Zhong et al. BIOMEDICINE & PHARMACOTHERAPY
- Partial PTEN deletion is linked to poor prognosis in breast cancer
- (2015) P. Lebok et al. BMC CANCER
- Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer
- (2015) Sarah L Larsen et al. BMC CANCER
- Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
- (2015) Stine Hole et al. BREAST CANCER RESEARCH AND TREATMENT
- Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
- (2015) Carlos Acevedo-Gadea et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
- (2015) C. X. Ma et al. CLINICAL CANCER RESEARCH
- A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
- (2015) H. M. Stern et al. CLINICAL CANCER RESEARCH
- Multi-Kinase Inhibitors
- (2015) Laura Garuti et al. CURRENT MEDICINAL CHEMISTRY
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases
- (2015) Anna-Mária Tökés et al. JOURNAL OF CLINICAL PATHOLOGY
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
- (2015) Bohuslav Melichar et al. LANCET ONCOLOGY
- AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
- (2015) R. Ribas et al. MOLECULAR CANCER THERAPEUTICS
- p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
- (2015) J. J. Tentler et al. MOLECULAR CANCER THERAPEUTICS
- PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
- (2015) Q Wang et al. ONCOGENE
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution
- (2015) Amanda Tse et al. PLoS One
- Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers
- (2015) Loredana Santo et al. SEMINARS IN ONCOLOGY
- p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion
- (2015) Xiaomei Qi et al. STEM CELLS
- Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy
- (2015) Liao Ning et al. TUMOR BIOLOGY
- MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer
- (2015) Zhen-Hua Wu et al. TUMOR BIOLOGY
- Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
- (2015) Dong-Hoe Koo et al. TUMOR BIOLOGY
- Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells
- (2015) Y Hu et al. Cell Death & Disease
- Targeting Breast Cancer with CDK Inhibitors
- (2015) Erica L. Mayer Current Oncology Reports
- PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo
- (2015) Kun-Chun Chiang et al. Drug Design Development and Therapy
- Characterization of DNA variants in the human kinome in breast cancer
- (2015) Divyansh Agarwal et al. Scientific Reports
- Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
- (2015) Xia Zhang et al. Scientific Reports
- Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options
- (2015) Joseph P. Burnett et al. Scientific Reports
- Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer
- (2015) Yan-Ru Zeng et al. BMC Urology
- Changing Treatment Paradigms in Metastatic Breast Cancer
- (2015) Cesar A. Santa-Maria et al. JAMA Oncology
- Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
- (2015) Huifeng Niu et al. Frontiers in Oncology
- Big Data for Precision Medicine
- (2015) Daniel Richard Leff et al. Engineering
- Aurora kinase a suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cells
- (2015) Ling-Zhi Xu et al. Oncotarget
- Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer
- (2015) Fares Al-Ejeh et al. Oncotarget
- 3-Phosphoinositide-Dependent Kinase 1 Controls Breast Tumor Growth in a Kinase-Dependent but Akt-Independent Manner
- (2015) Paolo Armando Gagliardi et al. NEOPLASIA
- Loss of PTEN Expression Is Associated With IGFBP2 Expression, Younger Age, and Late Stage in Triple-Negative Breast Cancer
- (2014) Sarah J. R. Dean et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The MAPK pathway across different malignancies: A new perspective
- (2014) Mauricio Burotto et al. CANCER
- Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro
- (2014) Giulia Marvaso et al. CANCER BIOLOGY & THERAPY
- Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
- (2014) N. E. Bhola et al. CANCER RESEARCH
- Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
- (2014) Eva Maria Ciruelos Gil CANCER TREATMENT REVIEWS
- Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists
- (2014) Denise A. Yardley Clinical Breast Cancer
- Therapeutic Targeting of Cancers with Loss of PTEN Function
- (2014) Lloye Dillon et al. CURRENT DRUG TARGETS
- Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K
- (2014) J. C. Liu et al. EMBO Molecular Medicine
- The kinome associated with estrogen receptor-positive status in human breast cancer
- (2014) M. C. Bruce et al. ENDOCRINE-RELATED CANCER
- New protein kinase inhibitors in breast cancer: afatinib and neratinib
- (2014) Xiaosong Zhang et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor-Initiating Cells and Overcomes Drug Resistance
- (2014) F.-M. Zheng et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- Sphingosine Kinase 1 Isoform-Specific Interactions in Breast Cancer
- (2014) Daniel Yagoub et al. MOLECULAR ENDOCRINOLOGY
- Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
- (2014) Richard Schroeder et al. MOLECULES
- A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells
- (2014) S Thrane et al. ONCOGENE
- Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells
- (2014) Mateusz Opyrchal et al. PLoS One
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Electrochemical assay of the relationship between the inhibition of phosphatidylinositol 3-kinase pathway and estrogen receptor expression in breast cancer
- (2013) Sha Zhu et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway
- (2013) Shira Peleg Hasson et al. Breast Care
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis
- (2013) Yaohui Wang et al. CURRENT MEDICAL RESEARCH AND OPINION
- Assessment of Aurora a Kinase Expression in Breast Cancer: A Tool for Early Diagnosis?
- (2013) Imen Ferchichi et al. DISEASE MARKERS
- Comprehensive analysis of PTEN status in breast carcinomas
- (2013) Natalie Jones et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition
- (2013) JAMES W. ANTOON et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
- (2013) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells
- (2013) P Cappello et al. ONCOGENE
- The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα+ breast cancer cells
- (2013) A B D'Assoro et al. ONCOGENE
- Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells
- (2013) ALEXEY A. LEONTOVICH et al. ONCOLOGY REPORTS
- PLK1 Signaling in Breast Cancer Cells Cooperates with Estrogen Receptor-Dependent Gene Transcription
- (2013) Michael Wierer et al. Cell Reports
- Synergistic Effect between Sphingosine-1-Phosphate and Chemotherapy Drugs against Human Brain-metastasized Breast Cancer MDA-MB-361 cells
- (2013) Ahlam Sultan et al. Journal of Cancer
- Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells
- (2012) Zhengzhi Zou et al. Autophagy
- Tamoxifen Resistance in Breast Cancer
- (2012) Min-Sun Chang Biomolecules & Therapeutics
- Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
- (2012) Wulf Siggelkow et al. BMC CANCER
- Defining the expressed breast cancer kinome
- (2012) Alicia A Midland et al. CELL RESEARCH
- Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation Treatment
- (2012) Abigail T. Berman et al. Clinical Breast Cancer
- Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
- (2012) J. R. Diamond et al. CLINICAL CANCER RESEARCH
- Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer
- (2012) James W Antoon et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
- (2012) Julia A Beaver et al. Future Oncology
- Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells
- (2012) MARTIN BLOCK et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway
- (2012) YU REN et al. ONCOLOGY REPORTS
- MAP Kinase Pathways
- (2012) D. K. Morrison Cold Spring Harbor Perspectives in Biology
- Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer
- (2011) Rulla M. Tamimi et al. BREAST CANCER RESEARCH AND TREATMENT
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
- (2011) J. Baselga ONCOLOGIST
- Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells
- (2010) Stephen Hiscox et al. BREAST CANCER RESEARCH AND TREATMENT
- Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer
- (2010) Barbro K. Linderholm et al. BREAST CANCER RESEARCH AND TREATMENT
- The Mitotic Kinase Aurora-A Induces Mammary Cell Migration and Breast Cancer Metastasis by Activating the Cofilin-F-actin Pathway
- (2010) L.-h. Wang et al. CANCER RESEARCH
- Triple-Negative Breast Cancer
- (2010) Shaheenah Dawood DRUGS
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
- (2010) Christopher P Gully et al. Molecular Cancer
- Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?
- (2010) A. A. Dar et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
- (2010) E. J. Meuillet et al. MOLECULAR CANCER THERAPEUTICS
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
- (2010) I Plaza-Menacho et al. ONCOGENE
- Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
- (2009) N Johnson et al. BRITISH JOURNAL OF CANCER
- Inhibition of the p38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells
- (2009) L. Chen et al. CANCER RESEARCH
- 3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma
- (2009) M. Maurer et al. CANCER RESEARCH
- Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization
- (2008) Elizabeth Iorns et al. BIOCHEMICAL JOURNAL
- New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death
- (2008) Margarida Cepa et al. BMC CELL BIOLOGY
- Do molecularly targeted agents in oncology have reduced attrition rates?
- (2008) Ian Walker et al. NATURE REVIEWS DRUG DISCOVERY
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started